Candidemia
Drug research and approvals for candidemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 3 studies of candidemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, and FDA has 2 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 3
- Trials authorized in Canada: 1
- FDA orphan approvals: 2
- EU medicines: 0
- Middle East Study of Infections in Patients With Hematological MalignanciesNCT07900542 · Not reported · Hamad Medical Corporation · starts Sep 15, 2024
- Comparison of Uncomplicated Candidemia Therapy Duration in Children and AdultsNCT05763251 · Not applicable · Arkansas Children's Hospital Research Institute · starts Sep 8, 2023
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or…NCT05421858 · Phase 3 · Basilea Pharmaceutica · starts Dec 11, 2024
Approved 4
- Anidulafungin1,3-beta-glucan synthase inhibitor
- Caspofungin1,3-beta-glucan synthase inhibitor
- VoriconazoleCytochrome P450 51 inhibitor
- RezafunginCandida inhibitor
Phase 3 6
- FluconazoleCytochrome P450 51 inhibitor
- Ibrexafungerp1,3-beta-glucan synthase inhibitor
- Interferon gamma-1bInterferon gamma receptor agonist
- FosmanogepixGPI-anchored wall transfer protein 1 inhibitor
- Micafungin1,3-beta-glucan synthase inhibitor
- Isavuconazole
How its trials ended
62 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 20 whose ending is known, 55% met their primary endpoint, 10% missed it and 35% stopped early.
- Completed, result not reported2947%
- Met its primary endpoint1118%
- Status unknown813%
- Stopped: other or unclear610%
- Ongoing58%
- Missed its primary endpoint23%
- Stopped: enrollment or feasibility12%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Feb 7, 2023 | A phase 3, multicenter, prospective, randomized, double-blind study of two treatment regimens for candidemia and/or invasive candidiasis: intravenous…Ibrexafungerp (SCY-078) | Scynexis | Closed |
| Jul 16, 2026 | RezzayoIn adults and pediatric patients 12 years of age or older who have limited or no alternative options for the treatment of candidemia and… | Mundipharma GmbH | Approved |
| Mar 22, 2023 | RezzayoIn patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis | Mundipharma GmbH | Approved |
| May 10, 2016 | IbrexafungerpTreatment of invasive Candida infections, including candidemia | GlaxoSmithKline LLC | Designated |
| Oct 20, 2014 | Isavuconazonium sulfateTreatment of invasive candidiasis/candidemia | Astellas Pharma Global Development, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA